Participant flow

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer · Source last updated 2025-10-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   160 milligram (mg) Selpercatinib administered orally, twice daily (BID) continuously in 21-day cycles.

   id

   FG000

   title

   Selpercatinib (TRT A)

2. description

   Pemetrexed 500 milligrams per meter squared (mg/m2) administered intravenously (IV) on Day 1, every 3 weeks (Q3W), plus investigator's choice of carboplatin area under the concentration versus time curve 5 (AUC 5 \[maximum dose 750 mg\]) IV, or cisplatin 75mg/m2 IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.

   id

   FG001

   title

   Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         0

      type

      Lost to Follow-up

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         2

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         93

      2. group Id

         FG001

         num Subjects

         30

      type

      On Treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         159

      2. group Id

         FG001

         num Subjects

         102

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         158

      2. group Id

         FG001

         num Subjects

         98

      type

      Received at Least One Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         61

      2. group Id

         FG001

         num Subjects

         70

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         98

      2. group Id

         FG001

         num Subjects

         32

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

If a participant has a recorded death on study, or is alive and being followed but off treatment, then the participant can be considered to be study completer.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice